Cabozantinib

Chemical formula: C₂₈H₂₄FN₃O₅  Molecular mass: 501.514 g/mol  PubChem compound: 25102847

Therapeutic indications

Cabozantinib is indicated for:

Renal Cell Carcinoma (RCC)

Population group: only adults (18 years old or older)

Cabozantinib is indicated for the treatment of advanced renal cell carcinoma (RCC):

  • in treatment-naïve adults with intermediate or poor risk
  • in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Hepatocellular carcinoma (HCC)

Population group: only adults (18 years old or older)

Cabozantinib is indicated as monotherapy for the treatment of hepatocellular carcinoma (HCC) in adults who have previously been treated with sorafenib.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2020: CABOMETYX Film-coated tablet
Structured Product Labeling (SPL/PLR) 2020: COMETRIQ Capsule
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈